What is William Blair’s Forecast for VRTX FY2025 Earnings?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Research analysts at William Blair lowered their FY2025 earnings per share (EPS) estimates for Vertex Pharmaceuticals in a note issued to investors on Monday, July 14th. William Blair analyst M. Minter now anticipates that the pharmaceutical company will post earnings of $16.17 per share for the year, down from their previous forecast of $16.20. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share. William Blair also issued estimates for Vertex Pharmaceuticals’ FY2026 earnings at $18.39 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The business had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.85 billion. During the same quarter in the prior year, the firm earned $4.76 EPS. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year.

VRTX has been the subject of a number of other research reports. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. JPMorgan Chase & Co. upped their price objective on Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an “overweight” rating in a research report on Monday. Leerink Partnrs cut Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 6th. Royal Bank Of Canada set a $420.00 price objective on Vertex Pharmaceuticals and gave the company a “sector perform” rating in a research report on Tuesday, June 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $535.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Fourteen research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $511.71.

Vertex Pharmaceuticals Stock Up 1.2%

VRTX stock opened at $469.55 on Wednesday. Vertex Pharmaceuticals has a 1-year low of $377.85 and a 1-year high of $519.88. The business has a fifty day moving average price of $448.13 and a 200-day moving average price of $461.63. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29. The stock has a market capitalization of $120.58 billion, a P/E ratio of -119.78 and a beta of 0.41.

Hedge Funds Weigh In On Vertex Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VRTX. ORG Partners LLC lifted its stake in shares of Vertex Pharmaceuticals by 17.4% in the 2nd quarter. ORG Partners LLC now owns 250 shares of the pharmaceutical company’s stock valued at $113,000 after purchasing an additional 37 shares during the last quarter. Ipswich Investment Management Co. Inc. lifted its stake in shares of Vertex Pharmaceuticals by 1.6% in the 2nd quarter. Ipswich Investment Management Co. Inc. now owns 5,608 shares of the pharmaceutical company’s stock valued at $2,497,000 after purchasing an additional 90 shares during the last quarter. Vision Capital Management Inc. lifted its stake in shares of Vertex Pharmaceuticals by 4.7% in the 2nd quarter. Vision Capital Management Inc. now owns 6,872 shares of the pharmaceutical company’s stock valued at $3,059,000 after purchasing an additional 307 shares during the last quarter. American National Bank & Trust lifted its stake in shares of Vertex Pharmaceuticals by 515.4% in the 2nd quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock valued at $36,000 after purchasing an additional 67 shares during the last quarter. Finally, Banque Pictet & Cie SA lifted its stake in shares of Vertex Pharmaceuticals by 48.9% in the 2nd quarter. Banque Pictet & Cie SA now owns 16,937 shares of the pharmaceutical company’s stock valued at $7,540,000 after purchasing an additional 5,564 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.